Table 1 Patient characteristics at ART initiation, and during follow-up (ART-LINC of IeDEA, 2008, n = 3,338)
Characteristics at ART initiation | N | |
|---|---|---|
Women (%) | 2,139 | (64.1) |
Median age (IQR*) | 34.0 | (30–41) |
Clinical stage (%) | ||
WHO I/II or CDC A/B | 1,078 | (32.3) |
WHO III | 977 | (29.3) |
WHO IV or AIDS | 1,019 | (30.5) |
Unknown | 264 | (7.9) |
Year of starting ART (%) | ||
1997 to 2001 | 351 | (10.5) |
2002 to 2003 | 917 | (27.5) |
2004 to 2005 | 1,629 | (48.8) |
2006 to 2007 | 441 | (13.2) |
First ART regimen (%) | ||
2NRTIs + 1NNRTI | 3,205 | (96.0) |
2NRTIs + 1PI | 133 | (4.0) |
Median CD4 cell count (IQR) | 107 | (46–179) |
HIV-RNA (%) | ||
[500–10,000[ copies/mL | 170 | (5.1) |
≥10,000 copies/mL | 1,942 | (58.2) |
Unknown | 1,226 | (36.7) |
Characteristics 6 months after ART initiation | ||
Median CD4 cell count (IQR) | 228 | (158–325) |
HIV-RNA (%) | ||
<500 copies/mL | 3,038 | (91.0) |
[500–10,000[ copies/mL | 155 | (4.6) |
≥10,000copies/mL | 145 | (4.4) |
Characteristics 12 months after ART initiation | ||
Median CD4 cell count (IQR) | 276 | (192–383) |
HIV-RNA (%) | ||
<500 copies/mL | 2,969 | (89.0) |
[500–10,000[ copies/mL | 187 | (5.6) |
≥10,000 copies/mL | 182 | (5.4) |
Median follow-up in years (IQR) | 1.6 | (1.2-2.4) |
Median number of CD4 measurements (IQR) | 2 | (2–3) |
Deaths at M18 (%) | 18 | (0.5) |
Lost to follow-up at M18 (%) | 325 | (9.7) |